Afinity Omega-3 Plus CoQ10 (Ubiquinol)
Natural health product licensed in Canada
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Huile de poisson Source : Engraulidae - en entier Potency : 470 mg Eicosapentaenoic acid | 1,000 mg | Not calculated |
| Huile de poisson Source : Engraulidae - en entier Potency : 240 mg Docosahexaenoic acid | Not specified | Not calculated |
| Ubiquinol Source : Ubiquinol | 150 mg | Not calculated |
Non-medicinal ingredients
Glycérine, Gélatine, Caramel, Eau purifiée, Poudre de caroube, Cire d'abeille, Palmitate d'ascorbyle, Lécithine, d-alpha tocophérol, Dioxyde de titane
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 1 Capsule ; maximum: 2 Capsule | 1 day |
Uses authorised in Canada
Text supplied in English because no French text is available.
Provides antioxidants. Source of omega-3 fatty acids for the maintenance of good health. Source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Helps maintain and/or support cardiovascular health. Helps to reduce serum triglycerides/triacylglycerols. Helps support cognitive health and/or brain function.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Product record
- Other names
- GenBioChem Omega-3 Plus CoQ10 (Ubiquinol)
- Licence holder
- Natural RF Life Sciences Inc.
- NPN or DIN-HM
- 80054440
- Status
- Active licence
- Licence date
- 1 October 2014
- Revision date
- 10 March 2025
- Form
- Capsule, molle
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80054440
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Huile de poisson
Read the warning, when it applies and the studies cited
FISH OIL
Route of administration: Oral
Cautions and warnings
Condition of application: Pain of rheumatoid arthritis.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
Condition of application: Healthy mood balance.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression.
- Ubiquinol
Read the warning, when it applies and the studies cited
UBIQUINOL
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Langsjoen and Langsjoen 2008; Rosenfeldt et al. 2007; Engelsen et al. 2003; Singh et al. 1999; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (6)
- Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Applies to products providing more than 100 mg of Ubiquinol, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Langsjoen and Langsjoen 2008; Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (4)
- Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Afinity Omega-3 Plus CoQ10 (Ubiquinol)”, https://compoatlas.com/en/supplements/canada/80054440-afinity-omega-3-plus-coq10-ubiquinol, updated 10 March 2025.